Bristol-Myers Squibb Company (BMY) investor relations material

Growth portfolio performance and outlook

• Growth portfolio delivered 12% year-over-year growth in Q1, with products like CAMZYOS, Reblozyl, and Breyanzi annualizing at over $1B, $1B, and $2B respectively.

• ELIQUIS continues to show double-digit growth, offsetting declines in legacy products facing generic competition.

• Pipeline includes potential for 10 new medicines and 30 lifecycle management indications by 2030.

• Company expects to be among the fastest-growing in the sector by the end of the decade.

Product and market dynamics

• CAMZYOS growth driven by increased diagnosis rates, new prescribers, and AI-enabled screening partnerships.

• Competition in the CAMZYOS market is emerging, but no significant differentiation observed so far.

• New phase III study for non-obstructive HCM initiated, aiming to address 30% of the market not currently served.

• Qvantig conversion rates exceed 10%, with a target of 30-40% over the next two years, and new data readouts expected to drive further growth.

Pipeline and innovation

• Milvexian positioned as a potential standard of care with a focus on superior bleeding profile compared to ELIQUIS.

• Secondary Stroke Prevention (SSP) and AFib indications seen as complementary, with data expected by year-end.

• Admilparant in IPF and PPF expected to be a significant player, with phase III results anticipated soon.

• CELMoDs (mezigdomide, iberdomide) expected to replace older therapies in multiple myeloma, with key readouts and approvals upcoming.